PHARMARON(300759)2025-01-21 10:04Revenue Projections - The estimated revenue for 2024 is projected to be between RMB 1,199,951.62 million and RMB 1,234,565.60 million, representing a year-on-year growth of 4% to 7%[4]. - The fourth quarter revenue is expected to grow by 4% quarter-on-quarter and 13% year-on-year, supported by the timely delivery of CMC services[11]. Profit Expectations - The net profit attributable to shareholders is expected to be between RMB 172,918.37 million and RMB 185,727.14 million, indicating a year-on-year increase of 8% to 16%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to decline by 24% to 29%, estimated between RMB 107,484.80 million and RMB 115,054.15 million[4]. - The adjusted net profit under non-IFRS is expected to be between RMB 156,081.32 million and RMB 165,598.47 million, reflecting a decrease of 13% to 18% compared to the previous year[5]. - The overall performance is influenced by a combination of increased revenue and non-recurring gains, leading to a net profit growth of 8% to 16%[12]. Non-Recurring Gains - Non-recurring gains and losses for the period are estimated to be between RMB 66,000 million and RMB 71,000 million, significantly higher than RMB 8,722.56 million in the previous year[12]. - The company has completed the sale of its stake in PROTEOLOGIX, resulting in a non-recurring gain of approximately RMB 56,000 million[7]. Order and Client Activity - The company anticipates a 20% increase in new order amounts year-on-year, driven by a recovery in global client inquiries and visits[11]. Financial Data Status - The financial data presented is preliminary and has not been audited by an accounting firm[10].